Advisors Asset Management Inc. Has $515,000 Stock Position in Exelixis, Inc. (NASDAQ:EXEL)

Advisors Asset Management Inc. boosted its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 3.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,853 shares of the biotechnology company’s stock after purchasing an additional 609 shares during the period. Advisors Asset Management Inc.’s holdings in Exelixis were worth $515,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Hsbc Holdings PLC boosted its position in Exelixis by 45.3% during the second quarter. Hsbc Holdings PLC now owns 90,211 shares of the biotechnology company’s stock valued at $2,031,000 after purchasing an additional 28,126 shares during the last quarter. Farallon Capital Management LLC boosted its position in Exelixis by 1.6% during the second quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company’s stock valued at $608,993,000 after purchasing an additional 424,000 shares during the last quarter. Seizert Capital Partners LLC boosted its position in Exelixis by 8.0% during the third quarter. Seizert Capital Partners LLC now owns 469,940 shares of the biotechnology company’s stock valued at $12,195,000 after purchasing an additional 34,875 shares during the last quarter. Los Angeles Capital Management LLC boosted its position in Exelixis by 124.0% during the third quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock valued at $46,473,000 after purchasing an additional 991,494 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Exelixis by 60.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 54,863 shares of the biotechnology company’s stock worth $1,424,000 after buying an additional 20,641 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Insider Transactions at Exelixis

In related news, EVP Jeffrey Hessekiel sold 25,000 shares of the firm’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $26.38, for a total transaction of $659,500.00. Following the completion of the sale, the executive vice president now directly owns 605,325 shares of the company’s stock, valued at $15,968,473.50. This trade represents a 3.97 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Patrick J. Haley sold 41,588 shares of the firm’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $34.36, for a total value of $1,428,963.68. Following the sale, the executive vice president now directly owns 288,665 shares of the company’s stock, valued at $9,918,529.40. This represents a 12.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 279,736 shares of company stock valued at $9,308,410. Corporate insiders own 2.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on EXEL shares. TD Cowen boosted their price target on Exelixis from $27.00 to $34.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Truist Financial boosted their price target on Exelixis from $33.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Guggenheim boosted their price target on Exelixis from $32.00 to $33.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Morgan Stanley boosted their price target on Exelixis from $26.00 to $28.00 and gave the stock an “equal weight” rating in a research report on Friday, October 11th. Finally, Bank of America boosted their price target on Exelixis from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, October 15th. One research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Exelixis currently has a consensus rating of “Moderate Buy” and an average price target of $31.44.

Exelixis Stock Down 1.4 %

Exelixis stock opened at $35.93 on Thursday. The business has a 50 day moving average price of $30.25 and a two-hundred day moving average price of $25.83. The stock has a market cap of $10.26 billion, a price-to-earnings ratio of 23.03, a price-to-earnings-growth ratio of 0.92 and a beta of 0.51. Exelixis, Inc. has a 12 month low of $19.20 and a 12 month high of $36.73.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The business had revenue of $539.50 million during the quarter, compared to analysts’ expectations of $490.31 million. During the same period in the prior year, the firm posted $0.10 EPS. Exelixis’s quarterly revenue was up 14.3% compared to the same quarter last year. On average, analysts expect that Exelixis, Inc. will post 1.69 earnings per share for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.